購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
B6-hALB/hTFRC Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
B6-hALB/hTFRC Mouse
製品名
B6-hALB/hTFRC Mouse
製品ID
C001730
系統名
C57BL/6NCya-Albtm1(hALB)Tfrctm1(hTFRC)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「B6-hALB/hTFRC Mouse(カタログ番号C001730)はサイアジェンから購入しました。」と引用してください。
HUGO-GT Humanized Models
Other Target Humanized Mouse Models
Blood-Brain Barrier
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
HUGO-GT Humanized Models
Other Target Humanized Mouse Models
Blood-Brain Barrier
基本情報
関連リソース
基本情報
遺伝子別名
HSA, FDAHT, PRO0883, PRO0903, PRO1341, T9, TR, TFR, p90, CD71, TFR1, TRFR, IMD46
染色体
Chr 4, Chr 3
さらに
系統詳細
The ALB gene encodes albumin, mainly produced in the liver, and is the most abundant protein in human plasma, accounting for 60% to 65% of total plasma protein. The proprotein encoded by ALB is processed to produce a functional protein, and the EPI-X4 peptide derived from this protein is an endogenous inhibitor of the CXCR4 chemokine receptor. Albumin plays a role in regulating plasma colloid osmotic pressure, helping to maintain blood circulation and isolating and transporting many metabolites within the body, especially insoluble hydrophobic metabolites [1]. Human Serum Albumin (HSA) is an important carrier protein involved in the transport of a variety of endogenous molecules, including hormones, fatty acids, and metabolic products, as well as exogenous drugs. As a natural carrier protein, HSA has multiple ligand binding sites and a plasma half-life of up to 19 days, making it a promising drug carrier. Several HSA-based drug delivery systems have been approved for clinical trials [2-3]. In addition, albumin is also the main transporter of zinc, calcium, and magnesium in plasma, binding approximately 80% of all plasma zinc and approximately 45% of circulating calcium and magnesium, with an affinity ranking of zinc > calcium > magnesium [4]. Diseases associated with the ALB gene include hyperthyroxinemia, familial serum albumin abnormality, and analbuminemia [5].
The Transferrin receptor (TFRC) gene encodes Transferrin Receptor 1 (TFR1), a protein that is expressed at low levels in most normal cells but shows increased expression in highly proliferative cells, such as basal epidermal cells, intestinal epithelium, and certain activated immune cells. Brain capillary endothelial cells, which constitute the blood-brain barrier (BBB), also express this receptor at high levels [6]. TFR1 plays a critical role in maintaining iron metabolism and homeostasis by facilitating receptor-mediated endocytosis of iron-bound transferrin (Tf) via Tf cycling, thereby promoting iron uptake [7]. Cellular iron deficiency can lead to apoptosis, while cellular transformation requires substantial iron to sustain proliferation, with iron overload contributing to tumor progression. The high expression of TFR1 in many tumors makes it a potential tumor marker, offering a target for therapies to inhibit tumor growth and metastasis [6]. Moreover, TFR1 is implicated in anemia and iron metabolism disorders. Studies have shown that elevated TFR1 expression in cardiomyocytes is associated with exacerbated inflammation in myocarditis patients [8].
B6-hALB/hTFRC mice are a dual gene humanized model of Alb and Tfrc, obtained by crossing B6-hALB (HSA) mice (Catalog number: C001492) with B6-hTFRC (CDS) mice (Catalog number: C001584). This model can be used for the development of ALB/TFRC-targeted therapeutic drugs, as well as for the research on drug development using human serum albumin (HSA) as a carrier or drug delivery across the blood-brain barrier (BBB), and for in vivo pharmacodynamic and pharmacokinetic studies.
参考文献
Caraceni P, Tufoni M, Bonavita ME. Clinical use of albumin. Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s18-25.
Lei C, Liu XR, Chen QB, Li Y, Zhou JL, Zhou LY, Zou T. Hyaluronic acid and albumin based nanoparticles for drug delivery. J Control Release. 2021 Mar 10;331:416-433.
Tiwari R, Sethiya NK, Gulbake AS, Mehra NK, Murty USN, Gulbake A. A review on albumin as a biomaterial for ocular drug delivery. Int J Biol Macromol. 2021 Nov 30;191:591-599.
Konopka K, Neilands JB. Effect of serum albumin on siderophore-mediated utilization of transferrin iron. Biochemistry. 1984 May 8;23(10):2122-7.
Arques S. Human serum albumin in cardiovascular diseases. Eur J Intern Med. 2018 Jun;52:8-12.
Candelaria PV, Leoh LS, Penichet ML, Daniels-Wells TR. Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents. Front Immunol. 2021 Mar 17;12:607692.
Xu W, Barrientos T, Mao L, Rockman HA, Sauve AA, Andrews NC. Lethal Cardiomyopathy in Mice Lacking Transferrin Receptor in the Heart. Cell Rep. 2015 Oct 20;13(3):533-545.
Kobak KA, Franczuk P, Schubert J, Dzięgała M, Kasztura M, Tkaczyszyn M, Drozd M, Kosiorek A, Kiczak L, Bania J, Ponikowski P, Jankowska EA. Primary Human Cardiomyocytes and Cardiofibroblasts Treated with Sera from Myocarditis Patients Exhibit an Increased Iron Demand and Complex Changes in the Gene Expression. Cells. 2021 Apr 6;10(4):818.
系統作製戦略

Figure 1. Gene editing strategy of B6-hALB (HSA) mice. Both the mouse Alb gene and the human ALB gene contain 15 exons. The mouse Alb gene sequence (upstream of Exon 1 to downstream of Exon 15) was replaced with the human ALB gene sequence using embryonic stem cell (ES) gene editing technology.


Figure 2. Gene editing strategy of B6-hTFRC(CDS) mice. TurboKnockout targeting technology was used to replace part of exon 2 of the mouse Tfrc gene with a human TFRC chimeric cDNA WPRE-BGH pA cassette. Gene-editing techniques were employed to knock out exons 10-13 of the mouse Tfrc gene.
適用分野
Development, screening, and efficacy evaluation of ALB/TFRC-targeted therapies;
Design and evaluation of albumin carrier drugs;
Research and evaluation of drug delivery across the blood-brain barrier (BBB).
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
